Overview

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic genotype (GT) 1 or 3 hepatitis C virus (HCV) infection.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Ribavirin
Sofosbuvir